TY - JOUR
AU - O’Neill, I.
AB - 1410 Correspondence 8 Targhetta C, Cabras MG, Angelucci E. Risk of HBV liver disease in became negative and remained undetectable throughout the isolated antiHbc patients receiving immuno-chemotherapy for non treatment period (52 weeks). Hodgkin lymphoma. Haematologica 2008; 93:e66. Our data, although limited to adalimumab and etanercept, 9 Lok AS, McMahon BJ. Practice Guidelines Committee, American indicate that for psoriatic patients who are also either occult Association for the Study of Liver Diseases (AASLD). Chronic hepa- or inactive carriers, it is safe to administer anti-TNF-a drugs. titis B: update of recommendations. Hepatology 2009; 50:857–61. However, as the risk of HBV reactivation is significantly higher 10 Nathan DM, Angus PW, Gibson PR. Hepatitis B and C infections in inactive carriers, different strategies must be adopted and anti-tumor necrosis factor-alpha: guidelines for clinical approach. J Gastroenterol Hepatol 2006; 21:1366–71. when an anti-TNF-a treatment is planned. In particular, occult HBV carriers can simply be monitored Key words: antitumour necrosis factor-a therapy, hepatitis B virus, inactive hepatitis with HBsAg and ALT ⁄ AST determinations every 3 months dur- B virus carrier, occult hepatitis B virus carrier, psoriasis ing the treatment and continued at the same timing for the Conflicts of interest: none declared. subsequent 
TI - Guidance on the use of biological agents in the treatment of oral mucosal disease
JO - British Journal of Dermatology
DO - 10.1111/j.1365-2133.2010.09704.x
DA - 2010-06-01
UR - https://www.deepdyve.com/lp/oxford-university-press/guidance-on-the-use-of-biological-agents-in-the-treatment-of-oral-D8H7OWEuQ7
SP - 1410
EP - 1411
VL - 162
IS - 6
DP - DeepDyve
ER -